XRP Bearish ETF Announces Revised Release Date

Teucrium’s repeated delays on its short XRP ETF signal either regulatory caution or internal hesitation about launching a leveraged bearish product into a volatile digital asset market. The fund’s 19 postponements contrast sharply with the rapid adoption of its bullish counterpart, raising questions about institutional appetite for inverse XRP exposure.

• Teucrium has delayed the short XRP ETF launch 19 times, with the newest deadline now set for October 11, 2026.
• The 2x long XRP ETF began trading on NYSE in April 2025 and has attracted $1.70 billion in cumulative inflows since launch.
• XRP peaked at $3.65 in July 2025 and now trades near $1.37, a drawdown exceeding 60% that the short ETF was designed to capture.

• 19 Total postponements of short XRP ETF since initial filing in April 2025
• $1.70B Cumulative inflows to long XRP ETF since its April 2025 launch
• $3.65 Peak XRP price in July 2025 versus current level near $1.37
• $190.5M Net inflows into XRP ETFs over the past 20 trading days

Teucrium has pushed back the launch of its short XRP ETF for the 19th time in less than 18 months. An SEC filing dated September 11 moved the earliest possible start date to October 11, 2026, continuing a pattern of monthly delays that began shortly before the company’s bullish XRP fund launched in April 2025. The short fund is structured to pay investors when XRP declines, using leveraged derivatives rather than holding the asset itself. Its long counterpart has meanwhile accumulated $1.70 billion in inflows despite a 60% price decline from XRP’s July 2025 peak of $3.65 to its current level near $1.37.

The context of Crypto ETF expansion

The approval of spot Bitcoin and Ethereum ETFs in 2024 fundamentally reshaped how institutional and retail investors access digital assets. Teucrium capitalized on this shift by filing for a leveraged long XRP ETF, which regulators approved relatively quickly, suggesting an appetite within the SEC for diversifying crypto product offerings beyond the two largest cryptocurrencies.

Inverse and leveraged crypto products remain more contentious from a regulatory perspective. The SEC has historically expressed concern about leverage introducing tail-risk dynamics that could harm retail investors unfamiliar with daily reset mechanics in leveraged funds. Short products in particular raise questions about custody, counterparty exposure, and whether retail investors understand the risks of betting against volatile assets using derivatives.

Nineteen Filings, No Explanation for the Delays

SEC public records show the same three-page document arriving roughly monthly since April 4, 2025, each time performing a single function: advancing the deadline by another month. The newest filing contains no explanation for the postponement, with strategy, fees, and risk disclosures remaining unchanged across all 19 submissions. The October 11, 2026 date marks only the first day the fund is permitted to trade, not a guaranteed launch date.

Teucrium has never publicly explained the holdup in any regulatory filing.

The first delay occurred just four days before the 2x long XRP ETF began trading on the New York Stock Exchange. Unlike regulatory blocks that might prevent a fund launch, these postponements represent Teucrium’s own deliberate choice to hold back the inverse product while advancing its bullish twin. XRP ETF inflows over the past 20 trading days totaled $190.5 million, with minimal redemptions, demonstrating sustained investor demand for upside exposure despite the asset’s sustained drawdown.

A Leveraged bet against XRP that never materialized

The short fund is designed to move twice as much as XRP does each day in the opposite direction. Rather than holding XRP directly, it would use derivative contracts with trading firms that pay out when the price drops. The mechanism would allow retail investors to access listed short exposure without managing counterparty risk or borrowing XRP themselves.

XRP peaked at $3.65 in July 2025 and has since declined to around $1.37, representing the exact scenario the short ETF was engineered to capture. Yet throughout this 60% drawdown, no listed short XRP product existed for retail investors seeking exposure to the decline. This represents a significant missed opportunity for Teucrium, as market participants who anticipated the downturn had no straightforward way to benefit through regulated U.S. exchanges.

Meanwhile, ordinary XRP holding funds arrived quickly and attracted substantial capital, with cumulative inflows now standing at $1.70 billion since their launch in April 2025. The contrast raises questions about whether Teucrium faces genuine regulatory obstacles or whether internal risk assessments about launching a short product into a volatile market have prompted the repeated deferrals.

Structural challenges for Inverse Crypto products

Leveraged inverse ETFs face inherent structural complications that bullish products do not. Daily reset mechanics mean that investors holding the fund across multiple days experience compounding effects that can diverge significantly from simply multiplying XRP’s directional move. Marketing such products to retail audiences without creating confusion remains challenging, and regulatory scrutiny of whether investors truly understand leverage has intensified since 2023.

Additionally, the counterparty dynamics of short derivatives differ from long positions. Teucrium would need to maintain relationships with trading firms willing to take the other side of bearish bets, and those firms may require collateral arrangements or impose terms that influence operational readiness.

What changes when and if the short fund finally launches

October 11 marks the 20th deadline for Teucrium’s inverse XRP ETF. After nearly two years of monthly postponements, the central question becomes whether launch conditions have meaningfully improved or whether the same structural constraints that have delayed the product will persist.

Teucrium has not disclosed its reasoning for any of the 19 prior delays, and no regulator has publicly blocked the fund’s approval, leaving open whether the company will actually proceed when October 11 arrives or issue another postponement notice before the deadline expires.

BlockWest is a news publication. Nothing here is investment advice. Read our disclaimer and editorial policy.